Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Illumina Inc ILMN

Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments... see more

NDAQ:ILMN - Post Discussion

Illumina Inc > End of Month - November 2020
View:
Post by R_J_ on Dec 03, 2020 1:33am

End of Month - November 2020

End of the Month Report for November 2020 for Illumina Inc.
-
ILMN closed on 11/30/2020 at US$ 322.09
ILMN closed on 10/30/2020 at US$ 292.70
-
This is a   10.0% gain, a US$ 29.39 gain, for November
-
S&P 500 Index, @ 3621.63 gained 10.8% in November. [14.9% above its MA(200) @ 3152.9]
-
Two Hundred Day Moving Average [MA(200)] stuff.
ILMN's  MA(200) ended November at US$323.99
ILMN is now 0.6% below its MA(200).
-
News Release on the ILMN Website in November
-
Nov 18, 2020     
Illumina to Webcast Upcoming Investor Conference Presentation
-
Nov 12, 2020     
Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit
-
Who is in charge?
Francis A. DeSouza, CEO
-
RJ
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities